Recent developments in the management of Huntington's disease.

TL;DR: A review on the new advances in the discovery of small molecules for the treatment of Parkinson's and Huntington's disease can be found in this paper , where the authors discuss the available pharmacological treatments to modulate the progression of neurodegeneration and to alleviate the motor symptoms in these diseases.

TL;DR: Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease focus on targeting the abnormal huntingtin protein and its toxic aggregates, as well as modulating the inflammatory and neurodegenerative processes.

TL;DR: The present review discusses the clinical and preclinical studies that investigate the neuroprotective effect of MTAXs (SS31, XJB-5-131, MitoQ, bezafibrate, rosiglitazone, meldonium, coenzyme Q10, etc.) in HD to understand the relevance of MTAXs in HD and enlighten the importance of MTAXs in future drug discovery and development.

TL;DR: An NH2-terminal fragment of mutant huntingtin was localized to neuronal intranuclear inclusions and dystrophic neurites in the HD cortex and striatum, and polyglutamine length influenced the extent of huntingtin accumulation in these structures.

TL;DR: The chromosomal localization of the Huntington's disease gene is the first step in using recombinant DNA technology to identify the primary genetic defect in this disorder.

TL;DR: The crystal structure of the human A2A adenosine receptor is determined, in complex with a high-affinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resolution and suggests a role for ZM 241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.

TL;DR: Predictive genetic testing and findings of neuroimaging studies show that Huntington's disease is emerging as a model for strategies to develop therapeutic interventions, not only to slow progression of manifest disease but also to delay, or ideally prevent, its onset.